Abstract | Despite their different targets, biologic agents used for blockade of TNF and IL-6, inhibition of T-cell co-stimulation and B-cell depletion all have similar beneficial effects on the outcome of rheumatoid arthritis (RA). This observation raises questions as to whether the targets of these therapies might all be involved in a common pathogenetic pathway. However, blockade of TNF and IL-6 has a similar inhibitory effect on joint damage progression in patients with either early or late disease. In comparison, B-cell depletion and inhibition of T-cell co-stimulation seem to have a somewhat delayed effect on joint damage (compared with cytokine inhibition), which suggests that these approaches affect upstream pathogenetic events. This article discusses these disparities and presents hypotheses as to whether clinical trial data can be used to determine at which point a biologic agent might interfere with the pathogenetic cascade in RA.
Introduction
The therapeutic landscape of rheumatoid arthritis (RA) has undergone revolutionary changes since the advent of biologic agents. An empiric approach has been the prevail ing strategy of drug discovery over the past century; in this approach the main pur pose of a clinical trial is to learn about the safety and efficacy of a given treatment in patients with a specific disease. These data are then used to obtain approval for marketing of the agent from the regulatory agencies of the country or region in question. If the trial data demon strate a reasonable benefittorisk ratio, the drug will be considered for approval regard less of whether its mode of action is known; for some key anti rheumatic drugs, such as methotrexate, the modes of action are yet to be elucidated.
Biologic agents differ from most pre vious therapies because they are designed to target an individual molecule deemed to be pivot ally involved in the pathogenesis of RA. The targets are usually cytokines, cytokine recep tors or some other cell surface molecules associated with differentiation or function of cells of the immune inflammatory system. Most new therapeutic agents for RA are being developed on the basis of this strategy; the results of clinical trials are consequently seen as not only indicators of efficacy and safety of a new agent, but also proof of a pathogenetic concept or, conversely, if no clinical benefit is shown the concept is often in terpreted as disproved.
Regardless of whether a primarily empiric or direct targeted approach is used to identify new treatments for RA, proving the via bility of a treatment and its presumed pathogenetic role can only be achieved by demonstrating the efficacy and safety of the new compound in a clinical trial, provided the trial is appro priately designed in terms of patient selec tion criteria and choice of end points. In this paradigm, the failure of a potential treatment to show efficacy in clinical trials would also cast doubt on the presumed pathogenetic role of the target, provided the agent indeed does in vivo what it is supposed to do.
In the current therapeutic environment, with the availability of outcome measures that describe different aspects of diseases such as RA-namely clinical, functional and structural end points-clinical trials can provide information that clearly goes beyond mere evidence of efficacy and safety. Clinical trials might also reveal vital informa tion that can close the gaps in our knowledge of pathogenetic pathways and clinical dis ease expression, and provide valuable hints leading to further insights and discoveries. In this Perspective, we discuss the evidence in support of this hypothesis.
Therapeutic targets in RA
The pathogenesis of RA is complex and thought to involve a number of different inter acting cells and molecules that provide numerous suitable targets for therapy ( Figure 1 ). Information obtained from dis secting the pathogenetic pathways of RA in vitro, ex vivo and in experimental models has resulted in the identification of many highly effective therapies. Indeed, TNF inhi bition was the first such successfully applied remedy and was identified on the basis of findings that indicated an essential involve ment of this cytokine in the inflammatory pathways leading to arthritis in experi mental animal models and humans. 1 Other c ytokines-produced by macrophages as well as fibroblasts, T cells and other cell types -are also highly expressed in patients with RA, [2] [3] [4] and constitute established or potential therapeutic targets. For example, IL6 recep tor blockade has become a widely applied therapy ( Figure 2 ). 4 RA is also thought to be an auto immune dis order characterized by the pro duction of autoantibodies. 5 Conse quently, if auto anti bodies do have an important patho genetic role, inhibiting Bcell function should be effi cacious; indeed, Bcell deple tion has become a standard biologic therapy ( Figure 3) . 6 More over, as immune responses-i ncluding auto immune reactions-usually require activa tion of T cells via presentation of an (auto)antigen and co stimulatory factors, inhibiting Tcell costimulation should also be effective in RA (Figure 4 ). This approach is certainly valid in the case of fusion proteins directed against CD80 and CD86 molecules, such as the con struct of cytotoxic Tlymphocyte antigen A with an Fc fragment of immunoglobulin G (CTLA4Ig, abatacept). 7 
OPINION
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Insight from failed therapies As described above, T cells and B cells, as well as proinflammatory cytokines, are involved in the pathogenesis of RA and could all, therefore, provide potentially suitable therapeutic targets. However, this simplistic approach soon becomes confus ing upon closer study. For example, IL1 is highly expressed in patients with RA, 2, 3 and conveys similar cellular and molecu lar effects to IL6 and TNF;
8 experimental animal models suggest a pivotal role for this cytokine in the pathogenesis of RA. 9 Nevertheless, IL1 blockade leads to, at best, weak clinical improvement, whether an IL1 receptor antagonist or an avid monoclonal antibody is used. 10, 11 The reasons underlying this lack of efficacy are difficult to explain and illustrate that high levels of a cytokine, or evidence of its importance in experimental disease models, do not necessarily mean that this factor has an essential role in the human disease, nor prove its usefulness as thera peutic target. Indeed, increased production of IL1 might be attributable to its induction by other molecules critically involved further upstream in the RA pathway: TNF is one such pivotal compound thought to increase IL1 levels. This reasoning also implies that the major pathogenetic effects of TNF are not mediated via IL1 but occur either directly or via other molecules. Consequently, modu lating TNF activity seems more useful in treating patients with RA than inhibition of IL1.
1 Nevertheless, clinical experience shows that some patients do respond well to IL1 inhibition, and this subgroup often fails to respond to other therapy. Although having bio markers that enable prediction of the qualitative and quantitative response profiles would be helpful, to the best of our knowledge, these are still lacking. 12 Importantly, the failure of some attempts does not preclude the usefulness of other treatments directed at the same cell popu lations (using agents with higher avidity or affinity for the target) or related cell popu lations (directed at specific subsets of cells that are pathogenetically involved). Indeed, depletion of certain subpopulations of T cells (such as CD4 + cells) 13 and interference with Bcell activation-for example, by inhibition of B lymphocyte stimulator (also known as tumor necrosis factor ligand superfamily member 13B or Bcell activating factor) or related molecules-are strategies that are not efficacious in patients with RA. 14, 15 The reasons for this observed lack of efficacy might include a lack of involvement of these targeted cell populations or pathways in RA, or insufficient efficacy of the agents tested.
Many other approaches that focus on mol ecules believed to be critically involved in RA have also failed to demonstrate therapeutic efficacy. 16 Additionally, the list of drugs that showed some efficacy in early phase clinical trials, but have not been developed further, is growing. The reason for this lies in the results of subsequent studies, which did not confirm that the clinical benefits were significant or showed that adverse events were more severe or more frequent than originally assumed. Thus, despite the similarities (if not identi ties) of their targets, various drugs have not shown an adequate degree of efficacy in clini cal trials; it is tempting to infer that at least some of the targets acted on by these agents are not valid in RA. Unfortunately, we cannot always explain the failure of certain agents directed against the same (or related) cell populations or cytokines as are targeted by successful therapies. Indeed, our knowledge is still incomplete for all targets-including those successfully inhibited-and, conse quently, clinical outcomes are difficult to predict. Thus, even when we have a sensible rationale for a given approach, the outcome of targeting a selected molecular pathway or component will not always meet our clini cal expectations. Of note, administration of combinations of biologic agents that target presumably different pathways have hither to always resulted in patients becoming more susceptible to infection 17, 18 with no appar ent additive or synergistic therapeutic effect, which suggests that redundancies in path ways or offtarget effects limit the presumed added efficacy of the treatment, but increase the serious adverse event profiles. This find ing is dis appointing, difficult to predict for biologics that have not yet been tested in combination and still awaits explanation. These discrepancies might reflect the uncer tainties at the foundations of our sci en tific processes. Finding an effective tar geted therapy might even seem to be no more than a game of chance within the logic derived from dissecting pathogenic path ways. Along this notion, some experimental models suggest that RA can be prevented or dramatically mitigated by inhibition or dele tion of particular genes, such as cytokine or certain receptor genes. [19] [20] [21] [22] Are these results misleading us by implying that RA might not be a complex disease but one that is driven by monogenic abnormalities or is treat able by targeting single genes or their products? Or are our assumptions about the complexity of events in the pathogenesis of RA correct?
Insight from effective therapy
Despite these uncertainties, dramatic advances have occurred in the RA therapeu tic arena. Blockade of TNF and IL6, inhi bition of Tcell costimulation and Bcell depletion are all highly effective and cur rently available therapies for RA. Interest ingly, however, all these approaches seem to have very similar clinical efficacy, at least when administered in combination with methotrexate, in any given population of patients with RA (early or late disease, and -with the exception of Bcell depletionpatients who test positive or negative for the presence of auto antibodies). 10, 23, 24 Although no headtohead trial comparing these four approaches has been performed, this obser vation raises the question of whether all effective therapies actually target a common final pathway in the pathogenesis of RA.
The results of the aforementioned studies of combination therapies targeting different pathways, which showed no added efficacy, emphasize the pertinence of this question. In this regard, the observation that patients with early RA experience more profound clinical efficacy (in terms of improvements in disease activity and functional scores) of any therapy-including synthetic or biologic DMARDs-than patients with established RA 23 is of interest and indicates that the path ways operating in late disease might differ from those in early disease. Indeed, cytokine profiles and Tcell activation patterns seem to differ in patients with early RA from those in patients with late RA. 25 Nevertheless, we still do not understand why clinical responses to all effective therapies are similar in patients with late disease, and also among those with early disease. We also do not know why established RA tends to be less clinically responsive to any treatment than early RA.
Insight from modes of action
Cytokine blockade Cytokine inhibition has wellknown direct downstream beneficial effects on inflamma tion and joint destruction in patients with RA ( Figure 2 ). However, cytokines might also be involved in feedback mechanisms that affect upstream events. Illustrating this point, TNF inhibition enhances Tregulatory (T REG ) cell activity, even in patients with RA. 26 Additionally, IL6 inhibition might exert important upstream effects by reducing the differentiation of T cells into Thelper17 (T H 17) cells and increasing T REG cell activity (Figures 1 and 2) . 27 B-cell depletion Eliminating B cells by targeting the CD20 cell surface differentiation antigen might remove a large population of cells replete with pathogenetically important cytokines, such as TNF and IL6. Concurrent deple tion of CD20 + nonB cells might convey additive effects. 28 Moreover, prevention of antigen presentation by eliminating B cells might convey additional effects of this tar geted approach by leading to a reduction in Tcell activation without primarily affecting costimulation ( Figure 3) . Thus, the role of B cells in the pathogenesis of RA might also have to be considered in the general context of intercellular communication: Bcell deple tion might not only lead to a reduction in autoantibodies, but also to an inhibition of Tcell reactivity either via deficient antigen presentation, elimination of a cell population capable to conveying costimulatory signals 24 or even activation of T REG cells. 29 
T-cell co-stimulation
Although the expected effect of CTLA4Ig is the inhibition of Tcell costimulation, induction of reverse signaling in, and thus inhibition of, macrophages might also occur ( Figure 4 ) in a similar fashion to the reverse signaling initiated by other costimulation molecules. 30 However, some evidence sug gests that this scenario might not be the case, although osteoclast generation can appar ently be directly inhibited by CLTA4Ig. 
Insights from clinical trials
Joint damage Explaining the mode of actions of socalled targeted therapies becomes a struggle given the similarity of the results obtained. At this juncture, we might be able to learn about the hierarchy of events by looking at results of clinical trials in greater detail. The views presented in this section are to a large extent speculative, albeit based on robust published data from clinical trials. As no conclusive headtohead trials of different biologic therapies have been conducted in patients with RA, we present indirect compari sons and provide our interpretation of these data as food for thought and further research. The studies we have selected for these com parisons are all large, pivotal phase III trials in which all primary and essentially all se condary end points were achieved.
We propose two hypotheses. First, that agents that block proinflammatory cyto kines, which are implicated in the presum ably most downstream inflammatory events in RA, will have a rapid inhibitory effect on the progression of joint damage. This effect would occur irrespective of the poten tial interference of these agents with the upstream effects of cytokines on effectors of the immune response, although this addi tional mechanism might contribute toward sustained efficacy of cytokineblocking treatment (Figure 2) . Second, that some bio logic therapies only target events far upstream in the presumed patho genetic cas cade of RA, with the result that their influ ence on the progression of joint damage will be delayed compared with that of treatments that affect downstream events. Their effect on joint destruction will be dependent on the downregulation of inflammatory cyto kines, which will occur some time after the interference with upstream events. Thus, more time would be needed for both Bcell depleting agents and Tcell costimulation inhibitors to affect the progression of struc tural changes at the point of their ultimate triggers (Figures 3 and 4) . We believe that the radiographic data from the respective clinical trials might provide key evidence for a potential hierarchy of the different molecular or cellular targets in the patho genetic process of RA. We have discovered remarkable consistency in the extent of the interference with progression of structural damage by all TNF inhibitors in patients with early or late RA ( Figure 5 ). In combi nation with metho trexate, TNF inhibitors retarded progression of joint damage in patients at 12 months by 80-100% com pared with control patients (Table 1) . 23, 33, 34 Moreover, even when half the dose of TNF inhibitors was employed, the inhibition of joint destruction was usually similar (Figure 5b ). The rapid onset of the effects of cytokine blockade on joint destruction was revealed by the considerable inhibition of damage progression only 6 months after initiating treatment. Further progression of radiographic changes after 6 months is almost absent (Figure 5 ). The only excep tion in this respect is golimumab, which did not reduce radiographic progression signifi cantly when combined with methotrexate in patients with late RA, presumably due to a previously unobserved very low progression in the control group. 35 Interestingly, the range of the structural effects exerted by TNF blockade plus metho trexate treatment are strikingly similar in patients with early and late RA, which is in contrast to the differences in clinical and functional efficacy (much more pronounced in early than late RA). Thus, we infer that the final pathways to joint destruction in patients with RA do not become refrac tory to cytokineblocking treatment with increasing disease duration, or with an increasing number of previous failed thera pies. Indeed, although progression of joint damage is strongly associated with the extent of disease activity-as assessed by swollen joint counts, acutephase reactant levels or composite disease activity measures at the initiation of therapy or on average over time-TNF blockade in combination with methotrexate severs this relationship. 36 Thus, the structural efficacy of this treat ment regimen, irrespective of disease dura tion and activity, supports the assumption that its effects occur primarily at the end of the autoimmune or inflammatory cascade. A biologic agent that seems to suppress the progression of structural damage to a comparable extent to TNF inhibitors is tocilizumab, which inhibits the effects of another proinflammatory cytokine, IL6 (Figure 5b) . 37 Notably, this effect is evident within the first 6 months of treatment and across the tested doses, as for TNF inhibitors, even if the lower dose has lower measured clinical efficacy. Additionally, tocilizumab in combination with methotrexate also dissoci ates the tight link between disease activity and joint damage. 38 Together, these observa tions support our hypothesis that agents that block proinflammatory cytokines will have a rapid inhibitory effect on the progression of joint damage.
By contrast, rituximab and abatacept reduce the progression of structural damage by about 40-70% versus control treatment, measured 12 months after the initiation of therapy (Table 1) . How ever, the inhibition of structural changes by these two agents is more pronounced between 6 and 12 months than between baseline and 6 months ( Figure 5 , Table 1 ). Indeed, in a trial of abata cept in patients with early RA, progression of damage was threefold greater in the first 6 months than in the subsequent 6 months. 7 Furthermore, in patients with early RA treated with rituximab, almost all the joint damage progression observed occurred during the first 6 months of the 12 month trial. 39 This pattern was also observed in patients receiving lowdose rituximab, which was less effective than the full dose at pre venting structural damage during the first 6 month but not the subsequent 6 months of treatment. As previously stated, given the lack of headtohead comparisons of the bio logic therapies for RA, we cannot unequivo cally conclude that any individual treatment regimen is better or worse than the others at slowing the progression of joint damage. Moreover, different scoring systems were used in the trials of TNF blockade (modi fied Sharp score or van der Heijde-Sharp score) and those of abatacept and rituximab (Genant-Sharp score). However, in all trials that assessed TNF inhibitors, the inhibition of joint damage progression over 12 months was consistently >70%, whereas in the trials of Bcelldepleting agents and inhibitors of Tcell costimulation the corresponding values were usually <70% at this time point. In the LITHE trial of tocilizumab, 37 the IMAGE trial 39 of rituximab and the AGREE trial 7 of abatacept, progression was almost completely halted (mostly >70% inhibition and only minimal, <0.2 points, progression as assessed by the Genant-Sharp score) during months 6-12, but not during the first 6 months of treatment ( Figure 5) . Thus, the use of different scoring systems between trials cannot account for the differences in damage progression profiles; importantly, between 6 and 12 months, all biologics perform similarly.
Together, these data suggest that inhibition of Tcell costimulation and Bcell depletion require more time to suppress joint destruc tion than cytokine blockade. These obser vations are in line with our hypothesis that some biologic therapies only target upstream events in the RA patho genetic cascade, and have a delayed effect on the progression of joint damage compared with cytokine blockade. In line with this hypo thesis, there is currently no evidence that ritu ximab and abatacept uncouple disease activity from joint damage; in its natural history or upon treatment with synthetic DMARDs, disease activity is linked to, and thus leads to, proportionate progression of radiographic changes. 40 Whether abatacept and rituximab dissociate this link as cytokine inhibitors do remains to be studied.
Although the differences between the effects exerted by cytokine inhibitors and other agents on joint damage, as depicted by radiography, during the first 6 months are too slight to have any real influence on the accrual of irreversible disability, 41 they might provide indirect insights into pathogenetic events. For example, the remarkable early efficacy of inhibitors of proinflammatory cytokines implies that blocking these molecules has a rapid influ ence not only on the inflammatory response but also on osteoclast and chondrocyte func tion. Conversely, the slight delay in onset of optimal beneficial effects on joint damage observed with therapies that target B cells and T cells could indicate that-in line with current assumptions about the pathogenesis of RA-these treatments target upstream events and take longer to affect the final common pathways, namely, generation of the proinflammatory cytokines that are the main mediators of joint damage (Figure 1 ). Assuming that, once activated, macrophages will continue secreting cytokines for some time, direct inhibition of these products ought to have the most rapid effects on the clinical disease expression. Inhibition of Tcell co stimulation, however, might be similarly effective but simply takes slightly longer to influence the furthest downstream, jointdamaging events, because the effects of inhibiting T cells on macrophage stimu lation might have to become fully opera tional before the downstream activities are downregulated by the treatment. Finally, Bcell depletion might have to first induce its effects on (auto)antibody and immune complex production, or on Tcell activation or T REG induction, before the downstream events are abrogated (Figures 3 and 4) .
Clinical findings
As previously indicated, progression of joint damage in patients with RA is highly cor related with overall levels of disease activity 37 in patients with late RA who had active disease despite methotrexate monotherapy. All patients continued methotrexate, which was given in combination with either a biologic agent or placebo. Only the trial of rituximab 52, 53 involved patients with late RA who had previously received tumor necrosis factor inhibitor treatment, but these patients also had active disease on methotrexate monotherapy. The radiographic scores used were partly different among the trials, as indicated on the y-axis. Abbreviation: RA, rheumatoid arthritis. ◀ PERSPECTIVES and with acutephase reactant levels and swollen joint counts at baseline and during treatment. 42 The delay in the onset of radio graphically detectable retardation of pro gression observed with Bcell depletion and inhibition of Tcell costimulation dis cussed above suggest that clinical efficacy of these two treatment strategies might also be delayed. However, little informa tion on the changes in disease activity over time has been reported in patients treated with these therapies and, therefore, making such inferences is difficult. Although TNF and IL6 receptor inhibition both lead to a rapid (within a few days) 4, 43 decrease in Creactive protein levels, the correspond ing data are not readily available for abata cept or rituximab treatment. However, data on the time course of some measures of RA -such as changes in overall disease activity score using 28 joints (DAS28), attainment of American College of Rheumatology 20% reduction (ACR20) or 50% reduction (ACR50) responses or achieving DAS28 remission criteria-have been presented in some of these studies. For example, at 8 weeks, ~20% of patients with early RA treated with etanercept plus methotrex ate attained DAS28defined remission, 33 about twice the proportion (~10%) of those treated with abatacept plus methotrexate. 7 Of course, these were separate (and not directly comparable) trials; firm deductions are, therefore, difficult to make and our interpretation is speculative. Nevertheless, in both studies, methotrexate monotherapy was the active control treatment and the 8week DAS28 remission rates in the control cohorts were similar (~4%) in both trials, supporting our interpretation. Furthermore, at 12 months, the proportions of patients in DAS28 remission were comparable (50% and 41% for the etanercept and abatacept trials, respectively), and the proportion of patients in remission in the control groups of these trials were also similar (28% and 23%, respectively). Moreover, a plateau effect with regard to the number of patients in DAS28 remission was seen at approxi mately 5-6 months for the TNF inhibitor etanercept, and at about 9-10 months for the Tcell costimulator abatacept, which also supports our hypothesis.
Similar data have not been presented for rituximab; however, looking at the time course of DAS28 score changes, a plateau effect can be seen in the control (metho trexate) arm of the IMAGE trial at around 6 months (similar to that in the control arms in the abovementioned studies of etanercept and abatacept), compared with around 9 months for the rituximab cohort. 39 We interpret these data as showing a differ ence in the time to achieve maximum effi cacy, and that the profoundness of response increases beyond the 6month time point. Given the tight relationship between clini cal surrogates of inflammation and joint damage, these features might also explain the observations of the initial larger changes in radiographic scores and subsequent strong reduction of joint damage progression observed in patients treated with abatacept and rituximab.
Evidence from animal models
Evidence from experimental animal models also supports the two hypo theses presented in this article. For example, collagen induced arthritis (CIA), the most commonly employed model of RA, is ameliorated thera peutically (after its induction) by inhibition of TNF or IL6. 44, 45 More over, the effect of TNF inhibition immediately halts the pro gression of clinical scores and paw swelling. 45 Bcell depletion, how ever, is only effective when administered preemptively (before induction of CIA). 46 Similarly, in another animal model of p roteoglycaninduced arthritis, Bcell depletion had to occur before clinical signs of arthritis manifested (though after its induction) to ameliorate disease in conjunction with reduced autoantibody levels, inhibition of Tcell reactivity 24 and upregulation of T REG cells. 29 Finally, pro phylactic inhibition of Tcell costimulation retards the onset of CIA, whereas therapeu tic application only somewhat ameliorates disease. 47, 48 These data suggest that interfer ing with Tcell costimulation using a mono clonal antibody raised to a costimulatory molecule is slow to develop efficacy, which contrasts with observations on TNF inhibi tion in the CIA model and further supports our hypothesis. As with our hypothesis for human RA, these animal studies seem to indicate a lag time for therapeutic effects to become evident when targeting upstream rather than downstream events.
Conclusions
Taken together, the clinical and radiographic data suggest that abatacept and rituximab interfere with events upstream of the final inflammatory pathways in RA, and need a few additional weeks compared with TNF blockade or IL6 inhibition to influence joint damage. By contrast, cytokine inhibitors, whether targeting TNF or IL6, operate in close proximity to inflammatory processes or affect them directly. These agents rapidly suppress the clinical manifestations of RA and, consequently, the associated joint damage. Given that RA is a chronic disease and that small radiographic changes do not materialize as a significant increase in irreversible disability, these findings are not pertinent from a clinical point of view. The data discussed convey that clinical trial data reveal highly informative matter beyond that described by their end points. In this context, the appropriate design of clini cal trials-with respect to the hypothesis, popu lation, drug dose, concomitant therapy, patient inclusion criteria, trial duration and end point selection-is crucial.
The many failed trials of promising tar geted therapeutic agents for RA indicate that trial data alone can lead to pivotal insights; theory can only guide our investigations so far. This Perspective aimed to highlight the potential information that clinical trials can provide about treatment modes of action that possibly have not been considered previously. Indeed, future efforts should focus on identifying appropriate thera peutic targets in RA by searching for new bio markers for treatment efficacy and pre diction of response to individual targeted therapies, and stimulating more interaction and collaboration between basic and clini cal scientists to address the pertinent ques tions on the effects of different treatment modalitie s in RA. 
